Group 1 - GIC Private Limited increased its stake in Sanhua Intelligent Control (02050) by purchasing 449,600 shares at a price of HKD 42.2533 per share, totaling approximately HKD 18.9971 million [1] - After the acquisition, GIC's total shareholding in Sanhua Intelligent Control reached approximately 33.5136 million shares, representing a 7.03% ownership stake [1]

香港联交所最新资料显示，10月28日，GIC Private Limited增持三花智控（002050）(02050)44.96万股， 每股作价42.2533港元，总金额约为1899.71万港元。增持后最新持股数目约为3351.36万股，持股比例为 7.03%。 ...

Core Insights - Orange reported solid third-quarter results for 2025, leading to an increase in annual EBITDAaL growth guidance to at least 3.5% [6][8][10] Financial Performance - Group revenues for Q3 2025 reached €9,993 million, a 0.8% increase year-on-year, with EBITDAaL growing by 3.7% to €3,437 million [2][40] - eCAPEX (excluding licenses) increased by 8.3% in Q3 2025, totaling €1,466 million, driven by investments in growth areas [2][10] - EBITDAaL after eCAPEX was €1,971 million, reflecting a 0.6% increase [2][41] Regional Performance - Africa & Middle East revenues grew by 12.2% in Q3 2025, driven by strong retail services growth of 13.1% [20][21] - France experienced a revenue decline of 3.7% in Q3 2025, attributed to competitive pricing pressures and trends in wholesale services [16][19] - Europe saw a revenue increase of 4.7%, supported by a strong performance in retail services and IT & Integration Services [24][25] Customer Growth - The total customer base surpassed 300 million globally, with 8.2 million new customers added in Q3 2025 [3][8] - Mobile Financial Services, particularly Orange Money, reported 44 million active users, contributing to value creation [5][28] Strategic Initiatives - Orange announced a non-binding joint offer with Bouygues Telecom and Free-Groupe iliad to acquire a significant portion of Altice's activities in France, aimed at enhancing network resilience and cybersecurity investments [4][5] - The company is focused on operational efficiency and cost control, which have positively impacted EBITDAaL growth and margins [6][10] Future Outlook - The company aims to maintain double-digit EBITDAaL growth in the Africa & Middle East segment for 2025 [23] - Orange plans to present the evolution of its "Lead the Future" strategy at the Capital Markets Day scheduled for February 19, 2026 [7]

香港联交所最新资料显示，10月16日，GIC Private Limited增持和铂医药(02142)69万股，每股作价 13.5791港元，总金额约为936.96万港元。增持后最新持股数目为6297.5万股，最新持股比例为7.05%。 ...

智通财经APP获悉，香港联交所最新资料显示，10月16日，GIC Private Limited增持和铂医药(02142)69 万股，每股作价13.5791港元，总金额约为936.96万港元。增持后最新持股数目为6297.5万股，最新持股 比例为7.05%。 ...

Core Viewpoint - Longyuan Power (0916.HK) experienced a decline of 4.35%, trading at HKD 7.91, with a market capitalization of HKD 66.1 billion following a share reduction by GIC Private Limited [1] Group 1: Shareholding Changes - GIC Private Limited reduced its stake in Longyuan Power by selling 7.928 million shares at an average price of HKD 8.3166 per share, amounting to approximately HKD 65.93 million [1] - After the sale, GIC's ownership percentage decreased from 7.11% to 6.87% [1]

另外，基石药业即将于10月19日在2025年欧洲肿瘤内科学会年会上，公布其全球首创的PD- 1/VEGF/CTLA-4三特异性抗体CS2009在约70例患者中的初步临床数据，这将是该类靶点药物的全球首 次临床数据发表，备受行业瞩目。与此同时，其另一款ADC药物CS5001的临床方案也将同步披露。 新加坡政府投资公司GIC Private Limited持续看好并加码基石药业(02616)。根据香港联交所最新资料， GIC于10月13日披露再度增持基石药业，持股数达88,618,000，持股比例达到6%，彰显其长期信心。较 此前权益披露新增持股超过820万股，其10月13日单日增持股票部分平均成本6.9576港币/股。 值得注意的是，这已是GIC在不到两个月内的第二次大举增持——此前8月18日，GIC曾大手笔增持基石 药业8040万股股份，耗资超6.3亿港元。 ...

格隆汇10月17日丨根据联交所最新权益披露资料显示，2025年10月13日，恒瑞医药(01276.HK)获GIC Private Limited在场内以每股均价82.7931港元增持48.62 万股，涉资约4025.4万港元。 | 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 費出或涉及的 每股的平均價 | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | (請參聞上述 * 註 | | 有投票權股 (日 / 月 / 年) | | | | | | 份自分比 | | | | | | | | | ( %) | | | CS20251016E00296 | 486,200(L) GIC Private Limited | 1101(L) | | HKD 82.7931 | 52.018.600(L) | 20.15(L)13/10/2025 | 增持后，GIC Private Limited最新持股数目为5201.86万股，持股比例由19.96%上升至20. ...

Group 1 - GIC Private Limited reduced its stake in Longyuan Power (001289)(00916) by selling 7.928 million shares at a price of HKD 8.3166 per share, totaling approximately HKD 65.934 million [1] - After the reduction, GIC's latest shareholding stands at approximately 228 million shares, representing a holding percentage of 6.87% [1]

Group 1 - GIC Private Limited increased its stake in Heng Rui Medicine (600276) by 486,200 shares at a price of HKD 82.7931 per share, totaling approximately HKD 40.254 million [1] - After the increase, GIC's total shareholding in Heng Rui Medicine reached 52,018,600 shares, representing a 20.15% ownership stake [1]